Pharyngitis Treatment Market Report 2026

The pharyngitis treatment market size has grown strongly in recent years. It will grow from $2.37 billion in 2025 to $2.5 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising incidence of upper respiratory infections, widespread use of antibiotics in primary care, availability of broad-spectrum antibiotics, expansion of hospital treatment protocols, growth of outpatient treatment settings.

The pharyngitis treatment market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing focus on precision infection management, rising demand for resistance-aware therapies, expansion of digital diagnosis platforms, growing investments in novel antibiotic development, increasing adoption of home-based treatment models. Major trends in the forecast period include increasing development of targeted antibiotic therapies, rising adoption of rapid diagnostic support tools, growing use of combination drug regimens, expansion of telemedicine-linked treatment models, enhanced focus on antimicrobial stewardship.

The increasing incidence of influenza is expected to drive the growth of the pharyngitis treatment market in the coming years. Influenza, commonly referred to as the flu, is a highly contagious respiratory illness caused by influenza viruses. Pharyngitis treatment is commonly used in the management of influenza, as it helps alleviate throat inflammation and irritation associated with the infection. These treatments focus on symptom relief and aid in preventing complications such as pneumonia and bronchitis. For instance, in July 2023, according to the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, during the 2022 to 2023 influenza season in the EU and EEA, the proportion of positive influenza specimens reached 28% between weeks 5 and 12 of 2023. Therefore, the rising incidence of influenza is contributing to the growth of the pharyngitis treatment market.

Major companies operating in the pharyngitis treatment market are concentrating on the development of innovative therapies such as oral monotherapy to improve patient compliance and offer convenient and effective treatment options. Oral monotherapy involves the use of a single medication administered orally to treat a specific condition, rather than combining multiple therapies to achieve therapeutic outcomes. For example, in December 2023, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration for Fabhalta (iptacopan), making it the first oral monotherapy approved for adults with paroxysmal nocturnal hemoglobinuria (PNH). This approval represents a notable advancement by providing a convenient treatment option that improves hemoglobin levels and reduces the need for blood transfusions.

In January 2024, iNova Pharmaceuticals (Australia) Pty Limited, an Australia-based pharmaceutical company, acquired Mundipharma’s Consumer Health business for an undisclosed amount. Through this acquisition, iNova aimed to expand its consumer healthcare portfolio and strengthen its presence in global over-the-counter markets, including products for sore throat and pharyngitis treatment. Mundipharma is a UK-based pharmaceutical company specializing in consumer healthcare products, including OTC solutions for sore throat, oral care, and other wellness categories.

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Aurobindo Pharma Limited, Sandoz Group AG, Alkem Laboratories Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd.

North America was the largest region in the pharyngitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharyngitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharyngitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pharyngitis treatment market by increasing costs of imported active pharmaceutical ingredients, finished antibiotics, diagnostic reagents, and medical delivery supplies used in oral and injectable therapies. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on imported APIs, while Asia-Pacific faces higher production and export costs. These tariffs are contributing to price pressure and supply chain complexity. However, they are also encouraging domestic API manufacturing, regional drug formulation, and strengthened local pharmaceutical supply chains.

The pharyngitis treatment market research report is one of a series of new reports that provides pharyngitis treatment market statistics, including pharyngitis treatment industry global market size, regional shares, competitors with a pharyngitis treatment market share, detailed pharyngitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pharyngitis treatment industry. This pharyngitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharyngitis treatment involves the management and care of individuals suffering from inflammation of the mucous membranes of the oropharynx, commonly referred to as the throat. Pharyngitis may result from various causes, including viral or bacterial infections, allergies, physical trauma, malignancies, reflux conditions, and exposure to certain toxins.

The primary drug classes used in pharyngitis treatment include beta-lactams, macrolides, cephalosporins, fluoroquinolones, tetracyclines, and others. Beta-lactams are antibiotics characterized by the presence of a beta-lactam ring in their chemical structure. The sources of infection are broadly categorized as viral and bacterial. Treatments are administered through different routes such as oral, intravenous, intramuscular, and others, and are utilized by end users including hospitals, homecare settings, specialty centers, and others.

The pharyngitis treatment market consists of sales of antibiotics, antiviral drugs and antifungal medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.